Donate to Science & Enterprise

S&E on Mastodon

S&E on LinkedIn

S&E on Flipboard

Please share Science & Enterprise

ImmunoGen, Novartis to Collaborate on Cancer Drugs

Drug vials (Hey Paul/Flickr)ImmunoGen Inc., a biotechnology company in Waltham, Massachusetts, said today it has a collaboration agreement with Novartis to discover and develop targeted anticancer therapeutics using antibodies to several antigen targets to be named by Novartis, a pharmaceutical manufacturer headquartered in Basel, Switzerland.

Under the agreement, Novartis will pay a $45 million fee to ImmunoGen for exclusive rights to use the company’s Targeted Antibody Payload (TAP) technology with antibodies to the antigen targets specified by Novartis. ImmunoGen says a TAP compound consists of a tumor-targeting manufactured antibody with a cancer-killing agent attached as a payload. The antibody delivers the payload specifically to tumor cells. Seven TAP compounds are now in clinical testing, either through ImmunoGen’s own product programs and those of its partners.

The agreement also provides that for each target resulting in an anticancer therapeutic, ImmunoGen is entitled to receive milestone payments potentially totaling $200.5 million plus royalties on any product sales. ImmuGen also will also be compensated for research and any manufacturing done on behalf of Novartis.

Related: Novartis to Develop Flu Vaccines with Synthetic Genomics

Photo: Hey Paul/Flickr

Comments are closed.